梁思颖,王 洁

慢性肾脏病(chronic kidney disease,CKD)在全球具有高发病率，其起病隐匿，早期症状不明显，病情发展具有不可逆性，并发症多。其中心脏瓣膜钙化(cardiac valve calcification,CVC)是慢性肾脏病患者中常见的一种并发症，其显著增加了心血管事件的风险与死亡率，因与CKD患者的预后密切相关而倍受关注。CVC的发生、发展是一个多因素参与的复杂病理过程，本文就CVC的发病机制及危险因素、诊断方式、治疗措施等的研究进行综述。

慢性肾脏病；心脏瓣膜钙化；发病机制；危险因素；诊断方式；治疗措施

[1] 赵云飞,彭辉,刘欢,等.瓣膜性心脏病与慢性肾脏病关系的研究进展[J].心脏杂志,2026(01):108-114. [2] Shu L,Yuan Z,Li F,et al.Oxidative stress and valvular endothelial cells in aortic valve calcification[J].Biomed Pharmacother,2023,163:114775. [3] 徐艳娇,马晓迎,杨星梦,等.慢性肾脏病患者心脏瓣膜钙化机制及危险因素的研究进展[J].河北医科大学学报,2025,46(01):37-41. [4] 王立婷.CXCL8介导瓣膜间质细胞-内皮细胞对话在慢性肾脏病瓣膜钙化中的机制研究[D].东南大学,2021. [5] Kutikhin A G,Yuzhalin A E,Brusina E B,et al.Genetic predisposition to calcific aortic stenosis and mitral annular calcification[J].Mol Biol Rep,2014,41(9):5645-5663. [6] Thanassoulis G,Campbell C Y,Owens D S,et al.Genetic associations with valvular calcification and aortic stenosis[J].N Engl J Med, 2013,368(6):503-512. [7] 陈小妹,张道友.尿毒症心瓣膜钙化发病机制研究进展[J].中国动脉硬化杂志,2012,20(03):283-288. [8]Strózecki P,Odrowaz-Sypniewska G,Manitius J.Cardiac valve calcifications and left ventricular hypertrophy in hemodialysis patients[J]. Ren Fail,2005,27(6):733-738. [9] Ureña P,Malergue M C,Goldfarb B,et al.Evolutive aortic stenosis in hemodialysis patients:analysis of risk factors[J].Nephrologie, 1999,20(4):217-225. [10] Massera D,Buzkova P,Bortnick A E,et al.Bone mineral density and long-term progression of aortic valve and mitral annular calcification:The Multi-Ethnic Study of Atherosclerosis[J].Atherosclerosis,2021,335:126-134. [11] 向泽礼.慢性肾脏病3-5期非透析患者心脏瓣膜钙化的影响因素[D].吉林大学,2023. [12] Wang A Y.Vascular and valvular calcification in chronic peritoneal dialysis patients[J].Int J Nephrol,2011,2011:198045. [13] 朱立平.慢性肾脏病钙磷代谢与营养指标､血镁及血管钙化的相关性分析[D].河北工程大学,2020. [14] Jan M I,Khan R A,Fozia,et al.C-Reactive Protein and High-Sensitive Cardiac Troponins Correlate with Oxidative Stress in Valvular Heart Disease Patients[J].Oxid Med Cell Longev,2022,2022:5029853. [15] 富宇婷郝丽荣.慢性肾脏病心脏瓣膜钙化的研究进展[J].中国医药导报,2016. [16] Phua K,Chew N W,Kong W K,et al.The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications[J]. Theranostics,2022,12(11):5189-5203. [17] 魏怀志,张蕾.慢性肾脏病与透析患者心脏瓣膜钙化的研究进展[J].世界最新医学信息文摘,2019,19(93):78-79. [18] 张丽黄平黄凌唐安戊黄新胜.老年心脏瓣膜钙化的病因探讨[J].岭南心血管病杂志,2000(02):107-109. [19] Reda S,Fawzy O,Sayed D,et al.Inactive Matrix Gla Protein in Relation to Renal and Cardiac Functions and Cardiac Valvular Calcification Among Type 2 Diabetes Patients[J].Clin Med Insights Endocrinol Diabetes,2023,16:733063190. [20] Manduteanu I,Simionescu D,Simionescu A,et al.Aortic valve disease in diabetes:Molecular mechanisms and novel therapies[J].J Cell Mol Med,2021,25(20):9483-9495. [21] 陈关芬,辛丽芹,杨丽华.腹透患者心血管钙化的发生率､分布特点及相关影响因素[J].河北医药,2016,38(16):2409-2412. [22] 刘炀.慢性肾脏病患者心脏瓣膜钙化及其危险因素分析[D].湖北民族大学,2021. [23] 张磊,王志奎,马金玲,等.维持性血液透析及腹膜透析患者心脏瓣膜钙化的评估[J].实用医学杂志,2016,32(07):1130-1132. [24] 田云还.维持性腹膜透析患者新发瓣膜钙化的危险因素及对预后的影响[D].苏州大学,2016. [25] Meng Z,Li Z,Zhang E,et al.Sevelamer Attenuates Bioprosthetic Heart Valve Calcification[J].Front Cardiovasc Med,2021,8:740038. [26] 贺靳贤.慢性肾脏病合并心脏瓣膜疾病的手术治疗[D].浙江大学,2010. [27] 沈玥,严玉澄.慢性肾脏病中血管钙化的早期诊治进展[J].中华临床医师杂志(电子版),2013,7(17):7684-7686. [28] 宋天宝.慢性肾脏病合并心脏瓣膜钙化的危险因素分析[D].吉林大学,2022. [29] Hoevelmann J,Mahfoud F,Lauder L,et al.Valvular heart disease in patients with chronic kidney disease[J].Herz,2021,46(3):228-233. [30] 汪晓晨.慢性肾脏病患者心脏瓣膜钙化的危险因素分析[D].东南大学,2020.

点击下载PDF